News | April 19, 2025
Aptar commences clinical study to accelerate FDA approval of SmartTrack
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The product will be launched in Q1FY26
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Subscribe To Our Newsletter & Stay Updated
